[an error occurred while processing this directive]
Skip to Main Content

Latest News

Advertisement
Advertise Here
June 6, 2011
Volume 89, Number 23
p. 8

Compound Prevents Neurodegeneration

Neurochemistry: Small molecule alleviates Alzheimer’s, Huntington’s symptoms in animals

Stu Borman

JM6
  • Print this article
  • Email the editor

Latest News



October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

Researchers have identified and tested a compound that reverses and prevents symptoms of neurodegenerative diseases like Alzheimer’s and Huntington’s in animal models (Cell, DOI: 10.1016/j.cell.2011.05.020; Curr. Biol., DOI: 10.1016/j.cub.2011.04.028). Neurodegeneration, the breakdown or death of neurons, causes losses in one’s ability to think, move, and communicate, often leading to death.

The compound, JM6, offers new hope for treating these diseases, for which new medications are urgently needed. Still, JM6’s safety and efficacy have yet to be confirmed in clinical trials.

The work was carried out by neuropharmacologist Robert Schwarcz of the University of Maryland School of Medicine; neurodegeneration specialist Paul J. Muchowski and his father, synthetic chemist Joseph M. Muchowski, both of Gladstone Institute of Neurological Disease; neurogeneticist Flaviano Giorgini of the University of Leicester, England; and coworkers. The research team hopes to have JM6 in human trials within two years, sponsored by a major drug firm or by a biotech company they are thinking about starting.

In animals, JM6 converts to an inhibitor of kynuren ine 3-monooxygenase, an enzyme that controls the kynurenine pathway, long believed to be implicated in neurodegeneration. This link was established to a large degree by Schwarcz’s group.

Levels of nerve-damaging kynurenine metabolites are elevated, and those of a neuroprotective one are lowered, in the blood of patients with neurodegenerative diseases. The researchers show that administering JM6 to animals with neurodegenerative diseases causes levels of the damaging and protective metabolites to normalize, leading to reversal and prevention of neuron damage.

JM6’s activity “seems like a fairy tale—almost too good to be true,” says Stephen Snyder, a deputy division director at the National Institute on Aging. “But intuitively you want JM6 to work out because it is simple and elegant, it’s good for the brain, and it appears to be nontoxic.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!